HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
Covered in this story
What has happened since
- Information Services Group Inc is up 25.1% since this was published, 68 days ago.
- MetLife is up 2.2% since this was published, 68 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $III yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Information Services Group Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.